Interacting Drugs |
Ergoloid mesylates vs Efavirenz |
Security Level |
|
Mechanism |
Efavirenz: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, the risk for peripheral vasospasm and ischemia may be increased. |
Management |
Avoid combination |
Ergoloid mesylates vs Efavirenz
Post Review about Ergoloid mesylates vs Efavirenz Click here to cancel reply.
Other Interactions of Ergoloid mesylates
Other Interactions of Efavirenz
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.